T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells

Leukemia

Volumn 26, Issue 2, 2012, Pages 365-367

  Mihara, K ^a   Bhattacharyya, J ^a   Kitanaka, A ^b   Yanagihara, K ^c   Kubo, T ^c   Takei, Y ^d   Asaoku, H ^e   Takihara, Y ^a   Kimura, A ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c YASUDA WOMEN'S UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; GREEN FLUORESCENT PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD38; RETROVIRUS VECTOR; SAR 650984; UNCLASSIFIED DRUG;

AUTOLYSIS; B CELL LYMPHOMA; BLOOD CELL; BONE MARROW; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL PROLIFERATION; CELL STRAIN; CELL SURFACE; CYTOTOXICITY; DONOR; HUMAN; LETTER; MYELOMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD38; HUMANS; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; T-LYMPHOCYTES;

EID: 84856760798     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.205     Document Type: Letter

References (8)

1. Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001; 25: 1-12. (Pubitemid 32012975)
2. Mihara K, Yanagihara K, Takigahira M, Imai C, Kitanaka A, Takihara Y et al. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. J Immunother 2009; 32: 737-743.
3. Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM et al. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 1994; 84: 3017-3025. (Pubitemid 24328093)
4. Ellis JH, Barber KA, Tutt A, Hale C, Lewis AP, Glennie MJ et al. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol 1995; 155: 925-937.
5. Flavell DJ, Boehm DA, Emery L, Noss A, Ramsay A, Flavell SU. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19-and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. Int J Cancer 1995; 62: 337-344.
6. Bolognesi A, Polito L, Farini V, Bortolotti M, Tazzari PL, Ratta M et al. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia. J Biol Regul Homeost Agents 2005; 19: 145-152. (Pubitemid 351515918)
7. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-1848.
8. Vooijs WC, Schuurman HJ, Bast EJ, de Gast GC. Evaluation of CD38 as target for immunotherapy in multiple myeloma. Blood 1995; 85: 2282-2284.